Matulane (procarbazine HCl)

Dosage of procarbazine hydrochloride is expressed in terms of procarbazine. Procarbazine hydrochloride dosage must be highly individualized based on clinical and hematologic response. Dosage is based on the patient's body weight; if the patient has abnormal fluid retention (e.g., edema, ascites), ideal body weight is used to calculate dosage. Clinicians should consult published protocols for the dosage of procarbazine hydrochloride and other chemotherapeutic agents and the method and sequence of administration.

Procarbazine therapy should be discontinued promptly in patients experiencing any of the following toxicities. Upon satisfactory recovery from toxicity, procarbazine therapy may be resumed at the discretion of the clinician.

Procarbazine hydrochloride is administered orally.

No dosing information is available for this tab.

No dosing information is available for this tab.

There is no enhanced messaging for this drug.

There are no contraindication interactions for this drug.

There are no severe interactions for this drug.

There are no moderate interactions for this drug.

There is no enhanced messaging for this drug.

There are no contraindication contraindications for this drug.

There are no severe contraindications for this drug.

There are no moderate contraindications for this drug.

There is no enhanced messaging for this drug.

There are no severe adverse reactions for this drug.

There are no less severe adverse reactions for this drug.

No enhanced messaging available.

No enhanced messaging available.

Procarbazine can cause fetal toxicity when administered to a pregnant woman, but potential benefits from use of the drug may be acceptable in certain conditions despite possible risks to the fetus. Although there are no adequate and well-controlled studies using procarbazine in pregnant women, malformations have been reported in infants born to women receiving procarbazine in combination with other antineoplastic agents during pregnancy. Procarbazine hydrochloride has been reported to cause fetal toxicity and teratogenicity in rats. Procarbazine is teratogenic in rats when given at dosages approximately 4-13 times the maximum recommended human dosage of 6 mg/kg daily. Although procarbazine has not been adequately studied in animals for its effects on perinatal or postnatal development, neurogenic tumors were observed in the offspring of rats given procarbazine 125 mg/kg IV on day 22 of gestation; compounds such as procarbazine that inhibit synthesis of DNA, RNA, and protein may be expected to have adverse effects on fetal and child development.

Procarbazine should be used during pregnancy only in life-threatening situations or severe disease for which safer drugs cannot be used or are ineffective. When procarbazine is administered during pregnancy or if the patient becomes pregnant while receiving the drug, the patient should be informed of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy with procarbazine.

It is not known whether procarbazine is distributed into milk. Because of the potential for tumorigenicity demonstrated in animal studies and the potential for serious adverse reactions to procarbazine in nursing infants, nursing should not be undertaken by women receiving the drug.

No enhanced messaging available.